Loading A detail
Loading ticker data...
Loading A detail
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce.
Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Chart data unavailable
CCLA Investment Management grew its holdings in shares of Agilent Technologies, Inc. (NYSE: A) by 1.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,047,488 shares of the medical research company's stock after purchasing an additional 19,518 shares
Agilent Technologies, Inc. (NYSE: A - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen research firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to
Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in Agilent Technologies, Inc. (NYSE: A) by 288.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,463 shares of the medical research company's stock after acquiring an additional 9,258
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea.
Agilent (A) reported earnings 30 days ago. What's next for the stock?
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica.
Nordea Investment Management AB lessened its stake in Agilent Technologies, Inc. (NYSE: A) by 5.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,774,119 shares of the medical research company's stock after selling 106,321 shares during the period. Nordea Investment Management AB
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a founda.
Danske Bank A S bought a new position in shares of Agilent Technologies, Inc. (NYSE: A) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 401,467 shares of the medical research company's stock, valued at approximately $51,528,000. Danske Bank A S owned approximately
Agilent Technologies, Inc. (A) Shareholder/Analyst Call Prepared Remarks Transcript
Aquatic Capital Management LLC reduced its position in Agilent Technologies, Inc. (NYSE: A) by 43.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 53,601 shares of the medical research company's stock after selling 41,359 shares during the period. Aquatic Capital Management LLC's holdings in
Citi swept through its life science tools and diagnostics coverage on Wednesday, opening a 90-day upside catalyst watch on Agilent Technologies ( NYSE:A ) while trimming its price target on Icon PLC ( NASDAQ:ICLR ) following a turbulent earnings season for the sector.
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company's expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing so.
Life sciences firm Agilent Technologies said on Monday that it will acquire clinical pathology firm Biocare Medical in an all-cash deal valued at $950 million.
Denver, CO and London, UK, 9 March 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, GHO Capital Partners LLP (“GHO”), a specialist investor in global healthcare, and Biocare Medical (“Biocare”), a global leader of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, today announce that Biocare has entered into an agreement to be acquired by Agilent Technologies (“Agilent”, NYSE:A), a prominent player in life sciences, diagnostics, and applied chemical markets.
